288 related articles for article (PubMed ID: 15739547)
1. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):216-22. PubMed ID: 15739547
[TBL] [Abstract][Full Text] [Related]
2. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
3. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
[TBL] [Abstract][Full Text] [Related]
4. Research on Parkinson disease.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):401. PubMed ID: 15739575
[No Abstract] [Full Text] [Related]
5. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
[TBL] [Abstract][Full Text] [Related]
6. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
Patel NK; Bunnage M; Plaha P; Svendsen CN; Heywood P; Gill SS
Ann Neurol; 2005 Feb; 57(2):298-302. PubMed ID: 15668979
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
Nutt JG; Burchiel KJ; Comella CL; Jankovic J; Lang AE; Laws ER; Lozano AM; Penn RD; Simpson RK; Stacy M; Wooten GF;
Neurology; 2003 Jan; 60(1):69-73. PubMed ID: 12525720
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
9. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Marks WJ; Ostrem JL; Verhagen L; Starr PA; Larson PS; Bakay RA; Taylor R; Cahn-Weiner DA; Stoessl AJ; Olanow CW; Bartus RT
Lancet Neurol; 2008 May; 7(5):400-8. PubMed ID: 18387850
[TBL] [Abstract][Full Text] [Related]
11. Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys.
Oiwa Y; Nakai K; Itakura T
Neurol Med Chir (Tokyo); 2006 Jun; 46(6):267-75; discussion 275-6. PubMed ID: 16794346
[TBL] [Abstract][Full Text] [Related]
12. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
Patel NK; Pavese N; Javed S; Hotton GR; Brooks DJ; Gill SS
Neurology; 2013 Sep; 81(13):1176-8. PubMed ID: 23946313
[TBL] [Abstract][Full Text] [Related]
13. GDNF delivery for Parkinson's disease.
Patel NK; Gill SS
Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
[TBL] [Abstract][Full Text] [Related]
14. Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.
Skalabrin EJ; Laws ER; Bennett JP
Mov Disord; 1998 Sep; 13(5):775-81. PubMed ID: 9756145
[TBL] [Abstract][Full Text] [Related]
15. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
[TBL] [Abstract][Full Text] [Related]
16. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys.
Zhang Z; Miyoshi Y; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1396-401. PubMed ID: 9316852
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
Lang AE; Gill S; Patel NK; Lozano A; Nutt JG; Penn R; Brooks DJ; Hotton G; Moro E; Heywood P; Brodsky MA; Burchiel K; Kelly P; Dalvi A; Scott B; Stacy M; Turner D; Wooten VG; Elias WJ; Laws ER; Dhawan V; Stoessl AJ; Matcham J; Coffey RJ; Traub M
Ann Neurol; 2006 Mar; 59(3):459-66. PubMed ID: 16429411
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
19. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
[TBL] [Abstract][Full Text] [Related]
20. Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
Gash DM; Zhang Z; Ai Y; Grondin R; Coffey R; Gerhardt GA
Ann Neurol; 2005 Aug; 58(2):224-33. PubMed ID: 16049934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
